Abstract
Mps1, also known as TTK, is a mitotic checkpoint protein kinase that has become a promising new target of cancer research. In an effort to improve the lead-likeness of our recent Mps1 purine lead compounds, a scaffold hopping exercise has been undertaken. Structure-based design, principles of conformational restriction, and subsequent scaffold hopping has led to novel pyrrolopyrimidine and quinazoline Mps1 inhibitors. These new single-digit nanomolar leads provide the basis for developing potent, novel Mps1 inhibitors with improved drug-like properties.
Keywords:
Cancer; Conformational restriction; Mps1; Protein kinase inhibitors; Purines; Pyrrolopyrimidines; Quinazoline; Scaffold hopping; Structure-based design; TTK.
Copyright © 2013 Elsevier Ltd. All rights reserved.
MeSH terms
-
Cell Cycle Proteins / antagonists & inhibitors*
-
Cell Cycle Proteins / metabolism
-
Cell Proliferation / drug effects
-
Drug Design
-
HCT116 Cells
-
Humans
-
Models, Molecular
-
Protein Binding
-
Protein Kinase Inhibitors / chemistry*
-
Protein Kinase Inhibitors / metabolism
-
Protein Kinase Inhibitors / pharmacology*
-
Protein Serine-Threonine Kinases / antagonists & inhibitors*
-
Protein Serine-Threonine Kinases / metabolism
-
Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Protein-Tyrosine Kinases / metabolism
-
Purines / chemistry*
-
Purines / metabolism
-
Purines / pharmacology
-
Pyrimidines / chemistry*
-
Pyrimidines / metabolism
-
Pyrimidines / pharmacology*
-
Pyrroles / chemistry*
-
Pyrroles / metabolism
-
Pyrroles / pharmacology*
-
Quinazolines / chemistry*
-
Quinazolines / metabolism
-
Quinazolines / pharmacology
-
Structure-Activity Relationship
Substances
-
Cell Cycle Proteins
-
Protein Kinase Inhibitors
-
Purines
-
Pyrimidines
-
Pyrroles
-
Quinazolines
-
pyrrolopyrimidine
-
Protein-Tyrosine Kinases
-
Protein Serine-Threonine Kinases
-
TTK protein, human
-
purine